Genmab and Synaffix Enter into License Agreement for ADC Technology
4/1 15:00
Media Release Synaffix to provide access to proprietary antibody-drug conjugate ( ADC ) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worl dwide development and commercialization of resulting therapie s Synaffix to...